Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

4(40%)

Results Posted

200%(2 trials)

Terminated

2(20%)

Phase Distribution

Ph not_applicable

20%

Ph phase_4

30%

Ph phase_3

10%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 2Efficacy & side effects

4(40.0%)

Phase 3Large-scale testing

1(10.0%)

Phase 4Post-market surveillance

3(30.0%)

N/ANon-phased studies

2(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

20.0%

1 of 5 finished

Non-Completion Rate

80.0%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(1)

Terminated(4)

Other(1)

Detailed Status

Recruiting4

Withdrawn2

Terminated2

unknown1

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 4

Trials by Phase

Phase 24 (40.0%)

Phase 31 (10.0%)

Phase 43 (30.0%)

N/A2 (20.0%)

Trials by Status

recruiting440%

unknown110%

withdrawn220%

terminated220%

completed110%

Recent Activity

4 active trials

Showing 5 of 10

recruitingphase_2

Add-on Diuretics in Acute Decompensated Heart Failure

NCT07372040

recruitingphase_2

Ertugliflozin in Chronic Heart Failure

NCT04438213

recruitingnot_applicable

Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure

NCT07199088

terminatedphase_2

Efficacy of Diuretics in Kidney Disease

NCT04542304

terminatedphase_4

Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance

NCT05986773

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT07372040Phase 2

Add-on Diuretics in Acute Decompensated Heart Failure

Recruiting

NCT04438213Phase 2

Ertugliflozin in Chronic Heart Failure

Recruiting

NCT07199088Not Applicable

Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure

Recruiting

NCT04542304Phase 2

Efficacy of Diuretics in Kidney Disease

Terminated

NCT05986773Phase 4

Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance

Terminated

NCT06414759Phase 4

Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload

Recruiting

NCT05633758Phase 2

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure

Withdrawn

NCT04163588Phase 3

Sequential Nephron Blockade in Acute Heart Failure

Unknown

NCT02606253Phase 4

Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure

Completed

NCT02047422Not Applicable

A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 10